Atlas market file · Equity · United States
20/20 Biolabs, Inc.AIDX
- Last close
- 0.4519
- Change
- +2.70%
- 96-bar range
- 0.4 – 2.19
- As of
- 6 Aug 2026
20/20 Biolabs, Inc. is a services-testing laboratories issuer listed as AIDX on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
AIDX
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 26 weekly closes (-96.94% over the window).
Source rail: Yahoo Finance chart API (AIDX). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for AIDX. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
AIDX public profile
Services-testing laboratories issuer. 20/20 Biolabs, Inc. is connected to current market context, cited company sources and its retained research file.
20/20 Biolabs, Inc. trades as AIDX on NASDAQ. 20/20 Biolabs, Inc. (AIDX) has a latest verified close of 0.4519, up 2.70%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files AIDX under USA Stocks for browsing.
What changed for 20/20 Biolabs, Inc. today
20/20 Biolabs (AIDX) ended Q1 2026 with $4.2M in cash but burned through $1.3M in operating activities while reporting a net loss of $2.2M on just $353k in revenue, per its latest 10-Q filing. The biotech, which claims to develop AI-powered blood tests for disease detection, spent only $153k on R&D during the period-less than 1% of its cash reserves.
The company’s official narrative, featuring images of sleek lab tech and a director of sales who 'rejoined after exceptional performance at Software AG,' contrasts sharply with its financial reality. Inventory fell by $11k in Q1, and liabilities now exceed equity by $400k. The firm’s recent 8-K filings focus on governance minutiae rather than addressing how it plans to monetize its 'cutting-edge' platform.
Despite the lackluster numbers, AIDX’s investor relations page continues to host a DEF 14A proxy statement and annual report, both available via a third-party proxy service. The company’s diluted EPS stood at -$0.28 for the quarter, with 7.7M shares outstanding. No significant product launches or regulatory approvals were disclosed in recent filings, though the board did approve routine governance updates in July 2026.
Chart watchers have little to grasp onto: no volume or price data is included in the source rail, and the company’s market cap isn’t disclosed. The lack of liquidity-implied by its penny-stock status and thin filings-makes technical analysis speculative at best. (source: SEC EDGAR submissions JSON, https://data.sec.gov/submissions/CIK0001139685.json)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
AIDX technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on AIDX
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep AIDX research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
AIDX FAQ
What is 20/20 Biolabs, Inc. (AIDX)?20/20 Biolabs, Inc. (AIDX) has a latest verified close of 0.4519, up 2.70%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
20/20 Biolabs, Inc. (AIDX) has a latest verified close of 0.4519, up 2.70%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for AIDX?20/20 Biolabs, Inc. (AIDX) has a latest verified close of 0.4519, up 2.70%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
20/20 Biolabs, Inc. (AIDX) has a latest verified close of 0.4519, up 2.70%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files AIDX under USA Stocks for browsing.
How often is the AIDX page updated?The AIDX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The AIDX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for AIDX?The AIDX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:AIDX. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The AIDX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:AIDX. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on AIDX?Yes. The workstation can open AIDX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open AIDX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this AIDX page investment advice?No. The AIDX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The AIDX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →